Welcome to our dedicated page for West Pharm Svcs news (Ticker: WST), a resource for investors and traders seeking the latest updates and insights on West Pharm Svcs stock.
West Pharmaceutical Services, Inc. (NYSE: WST) is a provider of injectable solutions and services that support the containment and delivery of medicines for pharmaceutical, biotechnology and generic drug companies. News related to WST often centers on its role in injectable drug administration, its proprietary product platforms and its contract manufacturing activities.
Company announcements frequently include quarterly and annual financial results, updates to revenue and earnings guidance, and details on performance in its Proprietary Products and Contract-Manufactured Products segments. Releases have highlighted trends in High-Value Product Components and High-Value Product Delivery Devices, as well as demand for self-injection devices for therapeutic areas such as obesity and diabetes.
West’s news flow also covers product and technology developments. Recent examples include the launch of the West Synchrony™ Prefillable Syringe System, described as a system-level solution for biologics and vaccines, and updates on the SmartDose® on-body delivery platform. The company has announced a definitive agreement to sell manufacturing and supply rights for the SmartDose® 3.5mL On-Body Delivery System and associated facilities to AbbVie, along with related information on continued supply and ongoing project commitments.
Investors following WST news will also see disclosures about capital allocation, such as dividends and share repurchases, as well as governance and leadership changes reported via press releases and Form 8-K filings. Conference participation and investor presentations are regularly announced, providing additional context on the company’s strategy and financial outlook. This news page aggregates such updates so readers can review West’s latest reported developments, financial communications and product-related announcements in one place.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
West Pharmaceutical Services (NYSE: WST) reported its Q1 2023 financial results on April 27, 2023. Net sales were $716.6 million, down 0.5% year-over-year, but organic sales increased by 2.3%. The diluted EPS dropped to $1.85, a decline of 19.2%. The company has raised its full-year net sales guidance to $2.965 billion to $2.990 billion, and adjusted-diluted EPS guidance to $7.50 to $7.65. A dividend of $0.19 per share was approved for Q3 2023, payable on August 2, 2023, to shareholders of record by July 26, 2023. Operational cash flow stood at $138.1 million, reflecting an 8.7% decrease, while free cash flow dropped 34.4% to $56.0 million. The firm anticipates continued growth despite a decline in COVID-19 related sales affecting its Biologics market unit.
West Pharmaceutical Services, a global leader in injectable solutions, announced the release date for its first-quarter 2023 financial results. The results will be published before the market opens on April 27, 2023. A conference call to discuss these results and future business expectations will be held at 9:00 a.m. Eastern Time on the same day. Investors can access a live audio-only webcast on the company’s Investor Relations website. To participate in the call, interested parties need to register in advance to receive dial-in details. A slide presentation will accompany the call and be available on the company's website. West Pharmaceutical reported $2.89 billion in net sales for 2022, marking its 100-year anniversary of innovation in healthcare.
West Pharmaceutical Services, Inc. (NYSE: WST) has announced a quarterly dividend of $0.19 per share, payable on May 3, 2023, to shareholders recorded as of April 26, 2023. This dividend reflects the company's ongoing commitment to returning value to its shareholders. In fiscal year 2022, West generated $2.89 billion in net sales, marking a significant milestone in its 100-year history of innovation in the injectable solutions market. The company supports pharmaceutical developers with reliable containment and delivery solutions, underscoring its critical role in healthcare.
West Pharmaceutical Services, Inc. (NYSE: WST) reported its fourth-quarter and full-year 2022 results, indicating a 3.0% decline in Q4 net sales to $708.7 million, with organic growth of 2.6%. Full-year 2022 net sales reached $2.887 billion, growing by 2.0% with 7.7% organic growth. Reported diluted EPS for Q4 was $1.36, dropping 29.5%, while full-year diluted EPS decreased 10.8% to $7.73. For 2023, the company expects net sales between $2.935 billion and $2.960 billion, with adjusted diluted EPS guidance of $7.25 to $7.40. A $1 billion share repurchase program was approved, with a focus on HVP manufacturing capacity to meet growing demand.
West Pharmaceutical Services (NYSE: WST) announced the expansion of its collaboration with Corning Incorporated, granting exclusive distribution rights for Corning Valor® Glass vials. The first product, West Ready Pack™ with Corning Valor® RTU Vials, uses SG EZ-fill® technology and aims to improve the packaging and delivery of injectable drugs. This collaboration, which includes a multimillion-dollar investment started in January 2022, focuses on enhancing patient safety and expanding access to healthcare. The combined system boasts benefits like proven container closure integrity and a sterile, ready-to-use design.
West Pharmaceutical Services (NYSE: WST) will release its fourth-quarter and full-year 2022 financial results on February 16, 2023, before market opening. A conference call to discuss these results will follow at 9:00 a.m. Eastern Time. Investors can access the live audio-only webcast via the Company’s Investor Relations website and participate by registering in advance. West will also attend the Barclays Global Healthcare Conference in Miami on March 14, 2023, and the KeyBanc Life Sciences & MedTech Investor Forum virtually on March 22, 2023. West, celebrating 100 years of innovation, generated $2.83 billion in net sales in FY 2021.